Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Abstract: Background: Previous studies suggest that a stable end-product of prostaglandin E2, the urinary metabolite PGE-M, is associated with colorectal cancer, and 1 study of relatively small sample size found an association with gastric cancer among women. In the present study we further investigate the PGE-M, Helicobacter pylori, and gastric cancer association. Methods: The present analysis included 359 prospectively ascertained gastric cancer cases and 700 individually matched controls from the Shanghai Women's and Men's Health Studies. Urinary PGE-M was measured by a liquid chromatography/tandem mass spectrometric method. Seropositivity to 15 H. pylori recombinantly expressed fusion proteins was detected by H. pylori multiplex serology. Results: Adjusting for H. pylori, increasing PGE-M was associated with higher risk of gastric cancer (quartile 4 vs 1: odds ratio [OR], 1.76 [95% confidence interval {CI}, 1.17-2.66], Ptrend = .004). This association remained after excluding those diagnosed within 2 years from sample collection (OR, 1.73 [95% CI, 1.12-2.65], Ptrend = .007). However it was no longer present among individuals with 10 or more years of follow-up (2-4.9 years: OR, 3.15 [95% CI, 1.11-8.91]; 5-9.9 years: OR, 2.23 [95% CI, 1.22-4.06]; 〉/=10 years: OR, 0.73 [95% CI, .31-1.70]). Compared to H. pylori-negative individuals with below-median PGE-M levels, H. pylori-positive individuals with above-median PGE-M levels had a 5-fold increase in the odds of gastric cancer (OR, 5.08 [95% CI, 2.47-10.43]). Conclusions: In China, higher PGE-M levels may indicate an increased risk of gastric cancer independent of the risk conferred by H. pylori infection status, particularly for cancers diagnosed within 10 years of sample collection.
    Type of Publication: Journal article published
    PubMed ID: 28402440
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; CANCER CELLS ; CELLS ; IN-VITRO ; CELL ; CLINICAL-TRIAL ; Germany ; human ; INHIBITION ; TOOL ; DISEASE ; DISEASES ; HISTORY ; NF-KAPPA-B ; FAMILY ; MEMBERS ; TYPE-1 ; virus ; PERFORMANCE ; TRIAL ; TRIALS ; CLINICAL-TRIALS ; CANCER-CELLS ; HERPES-SIMPLEX-VIRUS ; EPSTEIN-BARR-VIRUS ; traditional Chinese medicine ; HUMAN CYTOMEGALOVIRUS ; molecular ; review ; RE ; FAMILIES ; hepatitis C ; analysis ; artemisinin ; sesquiterpene lactones ; BIOLOGICAL-ACTIVITY ; USA ; hepatitis B ; immunology ; TOOLS ; microbiology ; cytomegalovirus ; viral ; MEDICINE ; PROFILE ; clinical trial ; MOLECULAR-MODES ; POSITION ; TRADITIONAL MEDICINE ; natural products ; NATURAL-PRODUCTS ; ANTIPARASITIC DRUGS ; HEPATITIS-C-VIRUS ; LIQUID-CHROMATOGRAPHIC DETERMINATION ; UNCOMPLICATED FALCIPARUM-MALARIA ; VIRAL-DIARRHEA-VIRUS
    Abstract: Traditional Chinese medicine commands a unique position among all traditional medicines because of its 5000 years of history. Our own interest in natural products from traditional Chinese medicine was triggered in the 1990s, by artemisinin-type sesquiterpene lactones from Artemisia annua L. As demonstrated in recent years, this class of compounds has activity against malaria, cancer cells, and schistosomiasis. Interestingly, the bioactivity of artemisinin and its semisynthetic derivative artesunate is even broader and includes the inhibition of certain viruses, such as human cytomegalovirus and other members of the Herpesviridae family (e. g., herpes simplex virus type 1 and Epstein-Barr virus), hepatitis B virus, hepatitis C virus, and bovine viral diarrhea virus. Analysis of the complete profile of the pharmacological activities and molecular modes of action of artemisinin and artesunate and their performance in clinical trials will further elucidate the full antimicrobial potential of these versatile pharmacological tools from nature
    Type of Publication: Journal article published
    PubMed ID: 18699744
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CELL ; IN-VIVO ; THERAPY ; DISEASE ; DISEASES ; PATIENT ; DNA ; INFECTION ; TRANSPLANTATION ; DYNAMICS ; MUTATION ; REPLICATION ; DNA-POLYMERASE ; AGENT ; VIRAL REPLICATION ; RECIPIENTS ; VIRAL LOAD ; USA ; immunology ; microbiology ; STEM ; cytomegalovirus ; viral ; block ; DNA-POLYMERASE MUTATIONS
    Abstract: This is the first report of treatment of cytomegalovirus infection with artesunate, for a stem cell transplant recipient with a newly identified foscarnet- resistant and ganciclovirresistant DNA polymerase L776M mutation. Artesunate treatment resulted in a 1.7 - 2.1- log reduction in viral load by treatment day 7, with a viral half- life of 0.9 - 1.9 days, indicating a highly effective block in viral replication
    Type of Publication: Journal article published
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: CLASSIFICATION ; DIAGNOSIS ; RISK ; GANCICLOVIR ; EBV ; B-LYMPHOCYTES ; POSTTRANSPLANT-LYMPHOPROLIFERATIVE-DISORDER ; SOLID-ORGAN TRANSPLANT ; CHRONIC ALLOGRAFT INJURY ; VIRAL LOAD CARRIAGE
    Abstract: Background. The epidemiology and morbidity of Epstein-Barr virus (EBV) infection in pediatric renal transplant recipients have been characterized insufficiently. Methods. In a prospective, multicenter study among 106 pediatric kidney allograft recipients aged 11.4 +/- 5.9 years, we investigated the epidemiology of EBV infection and the relationship between EBV load, EBV serology, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or symptomatic EBV infection, defined as flu-like symptoms or infectious mononucleosis). Results. EBV primary infection occurred in 27 of 43 (63%) seronegative patients and reactivation/reinfection in 28 of 63 (44%) seropositive patients. There was no association between the degree or duration of EBV load and EBV-related morbidity: The vast majority (17 of 18 [94%]) of patients with a high, persistent EBV load remained PTLD-free throughout a follow-up of 5.0 +/- 1.3 years, while 2 of 3 (66%) patients with EBV-related PTLD exhibited only a low EBV load beforehand. Eight of 18 (44%) patients with a high, persistent EBV load remained asymptomatic during a follow-up of 5.3 +/- 2.9 years. Multivariate analysis identified the EBV high-risk (D(+)/R(-)) serostatus (odds ratio [OR], 7.07; P 〈 .05), the presence of human leukocyte antigen (HLA)-DR7 (OR, 5.65; P 〈 .05), and the intensity of the immunosuppressive therapy (OR, 1.53; P 〈 .01) as independent risk factors for the development of a symptomatic EBV infection. Conclusions. Presence of EBV high-risk seroconstellation, HLA-DR7, and intensity of immunosuppressive therapy are significant risk factors for a symptomatic EBV infection, whereas there is no close association between the degree or duration of EBV load and EBV-related morbidity. Clinical Trials Registration. NCT00963248.
    Type of Publication: Journal article published
    PubMed ID: 23042966
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...